Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 801–900 of 1,002
Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
Noori, M., Jafari‐Raddani, F., Davoodi‐Moghaddam, Z., Delshad, M., Safiri, S., & Bashash, D. (2024) · Cancer Cell International · doi:10.1186/s12935-023-03183-3 · Cited by 26
Rachamalla, H. K., Madamsetty, V. S., Angom, R. S., Nakka, N. M. R., Dutta, S. K., Wang, E., Mukhopadhyay, D., & Pal, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03079-8 · Cited by 29
Desai, A., & Small, E. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0021 · Cited by 26
Glucocorticoids and immune checkpoint inhibitors in glioblastoma
Kelly, W., & Gilbert, M. R. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03439-2 · Cited by 26
Chan, S. L., Yip, T. C., Wong, V. W., Tse, Y., Yuen, B. W., Luk, H. W., Lui, R. N.-S., Chan, H. L., Mok, T. S. K., & Wong, G. L. (2020) · Cancer Medicine · doi:10.1002/cam4.3378 · Cited by 26
Cao, G., Wu, X., Wang, Z., Tian, X., Zhang, C., Wu, X., Zhang, H., Jing, G., & Yan, T. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034626 · Cited by 27
TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
Kato, R., Jinnouchi, N., Tuyukubo, T., Ikarashi, D., Matsuura, T., Maekawa, S., Kato, Y., Kanehira, M., Takata, R., Ishida, K., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100918 · Cited by 27
The role of immunotherapy in advanced renal cell carcinoma
Mondlane, E. R., Abreu‐Mendes, P., Martins, D. F., Cruz, R., & Mendes, F. (2021) · International braz j urol · doi:10.1590/s1677-5538.ibju.2020.0681 · Cited by 26
“Studies conducted with the combination of pembrolizumab plus axitinib and pembrolizumab plus lenvatinib showed improved outcomes and a manageable safety profile (53-55).”
BackgroundBiomarkers in renal cell carcinoma: Are we there yet?
Gulati, S., & Vogelzang, N. J. (2021) · Asian journal of urology · doi:10.1016/j.ajur.2021.05.013 · Cited by 30
“KEYNOTE-426 (phase III trial comparing pembrolizumab plus axitinib versus sunitinib) provided data from exploratory analysis regarding PD-L1 status [5].”
BackgroundMethodMantia, C. M., Jegede, O. A., Plimack, E. R., Powles, T. B., Motzer, R. J., Tannir, N. M., Lee, C., Tomita, Y., Voss, M. H., Choueiri, T. K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009495 · Cited by 28
Self-citationLoo, V., Salgia, M. M., Bergerot, P. G., Philip, E. J., & Pal, S. K. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00676-y · Cited by 25
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
Zhang, T., Pabla, S., Lenzo, F. L., Conroy, J. M., Nesline, M., Glenn, S. T., Papanicolau‐Sengos, A., Burgher, B., Giamo, V., Andreas, J., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1773200 · Cited by 27
“03) for PD-L1 low).(7) Based on these results, PD-L1 status does not currently play a role in treatment selection for first-line management of mRCC.”
BackgroundSchulz, G. B., Rodler, S., Szabados, B. E., Graser, A., Büchner, A., Stief, C. G., & Casuscelli, J. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.06.012 · Cited by 26
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Aeppli, S., Eboulet, E. I., Eisen, T. G., Escudier, B. J., Fischer, S., Larkin, J., Gruenwald, V., McDermott, D. F., Oldenburg, J., Omlin, A. G., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000852 · Cited by 26
Self-citationNovel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer
Ravi, P. K., Bakouny, Z., Schmidt, A. L., & Choueiri, T. K. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000477 · Cited by 25
Araújo, D. V., Wells, J. C., Hansen, A. R., Dizman, N., Pal, S. K., Beuselinck, B., Donskov, F. N., Gan, C. L., Yan, F., Tran, B., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.022 · Cited by 27
Self-citationZhuang, T., Case, K. B., Olsen, T. A., Brown, J. T., Carthon, B. C., Küçük, Ö., Goldman, J. M., Harris, W. B., Bilen, M. A., & Nazha, B. (2022) · Cancers · doi:10.3390/cancers14122867 · Cited by 30
“Keynote-426 was another phase 3 trial examining the efficacy of ICI/VEGF combination therapy [22].”
Inducing vascular normalization: A promising strategy for immunotherapy
Luo, X., Zou, W., Wei, Z., Yu, S., Zhao, Y., Wu, Y., Wang, A., & Lu, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109167 · Cited by 26
Emerging Targets in Clear Cell Renal Cell Carcinoma
Chen, Y., Rini, B. I., & Beckermann, K. E. (2022) · Cancers · doi:10.3390/cancers14194843 · Cited by 28
“There are four FDA approved combinations that belong to the IO/TKI category: pembrolizumab/axitinib [2] (KEYNOTE 426), avelumab/axitinib [3] (JAVELIN Renal 101), nivolumab/cabozantinib [4] (CheckMate 9ER), and pembrolizumab/lenvatinib [5] (CLEAR).”
BackgroundSelf-citationSchoenfeld, D. A., Moutafi, M. K., Martinez, S., Djureinovic, D., Merkin, R. D., Adeniran, A., Braun, D. A., Signoretti, S., Choueiri, T. K., Parisi, F., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007240 · Cited by 26
Xiong, L., Zhang, Y., Wang, J., Yu, M., Huang, L., Hou, Y., Li, G., Wang, L., & Li, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116158 · Cited by 25
Ashrafizadeh, M., Zhang, W., Tian, Y., Sethi, G., Zhang, X., & qiu, A. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10168-9 · Cited by 25
“That is why tyrosine kinase inhibitors with anti-angiogenic function have been used along with anti-PD-1/PD-L1 therapies in synergistic tumour suppression [44, 45].”
Soupir, A. C., Hayes, M. T., Peak, T. C., Ospina, O. E., Chakiryan, N. H., Berglund, A., Stewart, P. A., Nguyen, J. V., Segura, C. M., Francis, N. L., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03435-z · Cited by 33
Sun, X., Gan, L., Aru, N., Ge, L., Chen, B., & Liu, J. (2019) · Journal of Oncology · doi:10.1155/2019/1483406 · Cited by 25
“Regardless of PDL-1 expression, pembrolizumab combined with axitinib benefited patients in all risk groups (favorable, intermediate, and poor risk) [16].”
BackgroundStringhini, M., Probst, P., & Neri, D. (2020) · European Journal of Immunology · doi:10.1002/eji.201948433 · Cited by 25
Combinations using checkpoint blockade to overcome resistance
Morganti, S., & Curigliano, G. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1148 · Cited by 26
Herrmann, T., Ginzac, A., Molnar, I., Bailly, S., Durando, X., & Mahammedi, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4208 · Cited by 26
Development of patient‑derived tumor organoids and a drug testing model for renal cell carcinoma
Kazama, A., Anraku, T., Kuroki, H., Shirono, Y., Murata, M., Bilim, V. N., Ugolkov, A. V., Saito, K., & Tomita, Y. (2021) · Oncology Reports · doi:10.3892/or.2021.8177 · Cited by 27
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?
Tannock, I. F., Goldstein, D. A., Ofer, J., Gyawali, B., & Meirson, T. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00280 · Cited by 25
Lara, P. N., Villanueva, L., Ibáñez, C., Erman, M., Lee, J., Heinrich, D. A., Lipatov, O. N., Gedye, C. A., Gökmen, E., Acevedo, A., et al. (2024) · BMC Cancer · doi:10.1186/s12885-023-10971-7 · Cited by 28
Self-citationRaimondi, A., Randon, G., Sepe, P., Claps, M., Verzoni, E., de Braud, F., & Procopio, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174263 · Cited by 25
“The IMmotion151 [17] trial reported that the combination of the anti-PD-L1 atezolizumab plus bevacizumab prolonged PFS versus sunitinib, and the KEYNOTE-426 [16] study showed a significant benefit in terms of OS, PFS and ORR for the anti-PD1 agent pembrolizumab plus axitinib as compared to sunitinib.”
ResultPediatric and young adult renal cell carcinoma
Ray, S., Jones, R. J., Pritchard‐Jones, K., Dzhuma, K., van den Heuvel‐Eibrink, M. M., Tytgat, G. A. M., van der Beek, J. N., Oades, G. M., & Murphy, D. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28675 · Cited by 25
Hasanov, E., Gao, J., & Tannir, N. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000471 · Cited by 28
“From October 2016 to January 2018, 861 patients were randomized to receive pembrolizumab plus axitinib (pembro + axi) or sunitinib.(69) The primary endpoints of the study were PFS and OS among the ITT population.”
MethodImmune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy
Ho, A. K., Ho, A. M. ‐., Cooksley, T., Nguyen, G., Erb, J., & Mizubuti, G. B. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005029 · Cited by 24
Molecular Profiling of Exceptional Responders to Cancer Therapy
Bilušić, M., Girardi, D. M., Zhou, Y., Jung, K., Pei, J., Slifker, M. J., Chen, Q., Meerzaman, D. M., Alpaugh, K. R., Young, D., et al. (2020) · The Oncologist · doi:10.1002/onco.13600 · Cited by 26
“Recently, combination trials of TKIs and immunotherapy have shown excellent durable responses [41, 42].”
BackgroundSelf-citationResistance mechanisms to checkpoint inhibitors
Weiss, S. A., & Sznol, M. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.001 · Cited by 27
What morphology can teach us about renal cell carcinoma clonal evolution
Kapur, P., Christie, A. L., Rajaram, S., & Brugarolas, J. (2020) · Kidney Cancer Journal · doi:10.52733/kcj18n3-a1 · Cited by 26
Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Jang, A., Adler, D. M., Rauterkus, G. P., Bilen, M. A., & Barata, P. C. (2021) · Cancers · doi:10.3390/cancers13205065 · Cited by 27
“The phase 3 trial KEYNOTE-426 (NCT02853331) enrolled 861 advanced ccRCC patients to either pembrolizumab and axitinib (n = 432) or sunitinib (n = 429) [78].”
BackgroundInfluentialChanez, B., Caillol, F., Ratone, J., Pésenti, C., Rochigneux, P., Pignot, G., Piana, J. T., Brunelle, S., Walz, J. C., Salem, N., et al. (2021) · Cancers · doi:10.3390/cancers13215267 · Cited by 24
Xu, C., Zhang, K., Yang, F., Zhou, X., Liu, S., Li, Y., Ma, S., Zhao, X., Lü, T., Lu, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.773063 · Cited by 33
“However, the acquisition of therapeutic resistance in most patients has limited their further clinical application (7), which is closely correlated with the perfect linkage between tumor parenchymal and TME (8).”
BackgroundYanagisawa, T., Mori, K., Katayama, S., Mostafaei, H., Quhal, F., Laukhtina, E., Rajwa, P., Motlagh, R. S., Aydh, A., König, F., et al. (2022) · Immunotherapy · doi:10.2217/imt-2021-0207 · Cited by 24
Navani, V., Wells, J. C., Boyne, D. J., Cheung, W. Y., Brenner, D. M., McGregor, B. A., Labaki, C., Schmidt, A. L., McKay, R. R., Meza, L., et al. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.07.008 · Cited by 26
Self-citationProtein Expression of immune checkpoints STING and MHCII in small cell lung cancer
Dóra, D., Rivard, C. J., Yu, H., Pickard, S. L., László, V., Harkó, T., Megyesfalvi, Z., Gerdán, C., Dinya, E., Höetzenecker, K., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03270-w · Cited by 25
Fitzgerald, K. N., Düzgöl, C., Knežević, A., Shapnik, N., Kotecha, R. R., Aggen, D. H., Carlo, M. I., Shah, N. J., Voss, M. H., Feldman, D. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.10.017 · Cited by 24
The prospect of tumor microenvironment-modulating therapeutical strategies
Eulberg, D., Frömming, A., Lapid, K., Mangasarian, A., & Barak, A. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070243 · Cited by 35
Zeng, Y., Zhu, S., Wang, Z., Chen, J., Dai, J., Liu, Z., Sun, G., Liang, J., Zhang, X., Wang, Z., et al. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s393457 · Cited by 27
“further revolutionized the therapeutics of mRCC.(6,7) ICIs plus TKIs, and even nivolumab plus Ipilimumab have been recommended as the first-line treatment for clear cell renal cell carcinoma (ccRCC).”
BackgroundKushnir, I., Basappa, N. S., Ghosh, S., Lalani, A. A., Hansen, A. R., Wood, L. A., Kollmannsberger, C., Heng, D. Y. C., Bjarnason, G. A., Soulières, D., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.05.004 · Cited by 25
Self-citationChen, V. J., Hernandez‐Meza, G., Agrawal, P., Zhang, C. A., Xie, L., Gong, C. L., Hoerner, C. R., Srinivas, S., Oermann, E. K., & Fan, A. C. (2019) · Cancers · doi:10.3390/cancers11071000 · Cited by 25
“Currently, the treatment paradigm in mRCC is evolving from single-agent targeted th rapy to combination regim ns designed to maximize antitumor activity [8,9,15,22,23].”
BackgroundCarreau, N. A., Armand, P. A., Merryman, R. W., Advani, R. H., Spinner, M. A., Herrera, A. F., Ramchandren, R., Hamid, M. S., Assouline, S. E., Santiago, R., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16756 · Cited by 24
“In lung cancer and renal cell carcinoma, the addition of immunotherapy to chemotherapy and targeted agents has shown superior results to chemotherapy alone.(26,27) It is possible that, in our study, the CBT is working synergistically with the next line of therapy, despite its administration as an earlier line of thera…”
BackgroundAtkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Tarazi, J., Duggan, W. T., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.009 · Cited by 27
Self-citationZhao, Y., Liu, L., & Weng, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714483 · Cited by 27
Ren, S., He, J., Fang, Y., Chen, G., Ma, Z., Chen, J., Guo, R., Lin, X., Yao, Y., Wu, G., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100312 · Cited by 26
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
Choueiri, T. K., Motzer, R. J., Karam, J. A., Yip, W., Suárez, C., Ye, D., He, Z., Caglevic, C., Ferguson, T., Chang, Y., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2518245 · Cited by 31
Self-citationMiyake, M., Hori, S., Owari, T., Oda, Y., Tatsumi, Y., Nakai, Y., Fujii, T., & Fujimoto, K. (2020) · Cancers · doi:10.3390/cancers12113153 · Cited by 24
Guida, A., Sabbatini, R., Gibellini, L., Biasi, S. D., Cossarizza, A., & Porta, C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102157 · Cited by 24
Gu, X., Zhang, S., & Zhang, T. (2021) · Cells · doi:10.3390/cells10040869 · Cited by 26
Ciardiello, D., Maiorano, B. A., Parente, P., Rodriquenz, M. G., Latiano, T. P., Chiarazzo, C., Pazienza, V., Guerrera, L. P., Amoruso, B., Normanno, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020820 · Cited by 23
Yin, J., Elias, R. M., Peng, L., Levonyak, N. S., Asokan, A., Christie, A. L., Kubiliun, N. M., Brugarolas, J., & Hammers, H. J. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.01.017 · Cited by 24
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma
Santoni, M., Massari, F., Matrana, M. R., Basso, U., Giorgi, U. D., Aurilio, G., Buti, S., Incorvaia, L., Rizzo, M., Martignetti, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.035 · Cited by 24
Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma
Cardenas, L. M., Deluce, J. E., Khan, S., Gulam, O., Vareki, S. M., Fernandes, R., & Lalani, A. A. (2022) · Current Oncology · doi:10.3390/curroncol29080429 · Cited by 24
“Pembrolizumab (anti-PD-1 antibody) plus axitinib (VEGF-TKI) have become global standards after the combination improved OS compared to sunitinib in the KEYNOTE-426 trial [7].”
BackgroundGreene, C., Attwood, K. M., Sharma, N. J., Balderman, B., Deng, R., Muhitch, J. B., Smith, G. J., Gross, K. W., Xu, B., & KAUFFMAN, E. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923043 · Cited by 23
Sheng, X., Ye, D., Zhou, A., Yao, X., Luo, H., He, Z., Wang, Z., Zhao, Y., Ji, Z., Zou, Q., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.025 · Cited by 24
Yano, Y., Ohno, T., Komura, K., Fukuokaya, W., Uchimoto, T., Adachi, T., Hirasawa, Y., Hashimoto, T., Yoshizawa, A., Yamazaki, S., et al. (2022) · Cancers · doi:10.3390/cancers14225659 · Cited by 24
Sang, Y. B., Yang, H., Lee, W. S., Lee, S. J., Kim, S., Cheon, J., Kang, B., Kim, C. W., Chon, H. J., & Kim, C. (2022) · Cancers · doi:10.3390/cancers14235985 · Cited by 29
“In a pivotal KEYNOTE-426 trial, pembrolizumab and axitinib (Pembro/Axi), a first-line treatment for RCC patients, showed superior efficacy over sunitinib, regardless of the international metastatic RCC database consortium (IMDC) risk group [4].”
BackgroundMethodNakamura, A., Yamaguchi, O., Mori, K. P., Miura, K., Tamiya, M., Oba, T., Yanagitani, N., Mizutani, H., Ninomiya, T., Kajiwara, T., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.025 · Cited by 25
Chehrazi‐Raffle, A., Muddasani, R., Dizman, N., Hsu, J., Meza, L., Zengin, Z. B., Malhotra, J., Chawla, N. S., Dorff, T. B., Contente‐Cuomo, T., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00543 · Cited by 29
“Line of therapy, median (range) 2 (1-4) 1 (1-2) .”
Zhang, T., Forde, P. M., Sullivan, R. J., Sharon, E., Barksdale, E., Selig, W. K. D., Ebbinghaus, S., Fusaro, G., Günenç, D., Battle, D. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006555 · Cited by 23
“14 However, crosstalk between T cells, antigen-presenting cells, and cancer cells occurs within the tumor microenvironment (TME) and includes many more molecules and interactions.”
Self-citationWang, Y., Cui, C., Deng, L., Wang, L., & Ren, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127128 · Cited by 23
“which displayed promising treatment efficacy in some solid tumours (2–9), such as atezolizumab plus bevacizumab for NSCLC (trial of IMpower150) (18) and HCC (Imbrave150) (19), avelumab plus axitinib for RCC (20), pembrolizumab plus axitinib for RCC (KEYNOTE-426) (21), pembrolizumab plus lenvatinib for RCC (CLEAR) (22)…”
BackgroundTasaki, Y., Hamamoto, S., Sugiyama, Y., Tomiyama, N., Naiki, T., Etani, T., Taguchi, K., Matsuyama, N., Sue, Y., Mimura, Y., et al. (2023) · International Journal of Urology · doi:10.1111/iju.15220 · Cited by 25
An, Y., Pu, N., Jia, J.-B., Wang, W., & Liu, L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188958 · Cited by 26
Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Martin, S. D., Bhuiyan, I., Soleimani, M., & Wang, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154987 · Cited by 28
“Moreover, the phase III clinical trials CLEAR and KEYNOTE-426 demonstrated improved overall survival for patients receiving ICIs without significant differences between PD-L1-high and -low groups [68,159].”
BackgroundAlbiges, L. K., McGregor, B. A., Heng, D. Y. C., Procopio, G., de Velasco, G., Taguieva-Pioger, N., Martín-Couce, L., Tannir, N. M., & Powles, T. B. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102652 · Cited by 25
Self-citationEnhanced cellular therapy: revolutionizing adoptive cellular therapy
Xu, M., Zeng, N., Liu, C., Sun, J., An, Y., Zhang, S.-H., Xu, J., Zhong, X., Ma, S., He, H., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00506-6 · Cited by 25
“…as lpilimumab combined with nivolumab for BRAF wt metastatic melanoma) [231], ICI combined with chemotherapy (such as pembrolizumab combined with pemetrexed for NSCLC) [232], and ICI combined with targeted therapy (such as pembrolizumab combined with axitinib for renal cell carcinoma) [231, 233].”
BackgroundRebuzzi, S. E., Fornarini, G., Signori, A., Buti, S., Procopio, G., Giorgi, U. D., Pignata, S., Naglieri, E., Maruzzo, M., Banna, G. L., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12319-1 · Cited by 25
Immunotherapy for renal cell carcinoma
Sheng, I. Y. F., & Rini, B. I. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1628946 · Cited by 24
“26% CR 3% KEYNOTE 426 [42] 861 Pembrolizumab + Axitinib vs.”
Self-citationEvolving treatment paradigm in metastatic non clear cell renal cell carcinoma
Gulati, S., Philip, E. J., Salgia, S. K., & Pal, S. K. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100172 · Cited by 23
Pourmir, I., Noel, J., Simonaggio, A., Oudard, S. M., & Vano, Y. A. (2021) · World Journal of Urology · doi:10.1007/s00345-020-03528-x · Cited by 24
“First of all, the scoring method used to calculate PD-L1 varies across studies: in the KEYNOTE 426, a combined positive score (CPS) score was used (all PD-L1+ cells divided by number of tumor cells × 100), whereas only PD-L1+ tumor cells (TC) were counted in the ChecKMate 214 study and only PD-L1+ immune cells (IC) we…”
BackgroundMethodIGLL5 is correlated with tumor‐infiltrating immune cells in clear cell renal cell carcinoma
Xia, Z., Wang, X., Cai, L., Jian, W., & Zhang, C. L. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13085 · Cited by 25
Güven, D. C., Aksun, M. S., Şahin, T. K., Aktepe, O. H., Yildirim, H. Ç., Taban, H., Ceylan, F., Kertmen, N., Arık, Z., Dızdar, Ö., et al. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06139-3 · Cited by 24
“Although the absolute risk of the VTE with these combinations is unknown, there were two deaths due to VTEs in the pembrolizumab plus axitinib arm in the KN426 study [25], which deserves caution.”
BackgroundReal-world experience with pembrolizumab in patients with advanced soft tissue sarcoma
Liu, J., Fan, Z., Bai, C., Li, S., Xue, R., Gao, T., Zhang, L., Tan, Z., & Fang, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-49 · Cited by 25
“In addition, some clinical trials have shown that combining chemotherapy, targeted therapy, and radiotherapy can improve the response rate to ICIs (19-22).”
BackgroundInfluentialVon Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer
Shulman, M., Shi, R., & Zhang, Q. H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.05.016 · Cited by 25
Precision Bayesian phase I‐II dose‐finding based on utilities tailored to prognostic subgroups
Lee, J., Thall, P. F., & Msaouel, P. (2021) · Statistics in Medicine · doi:10.1002/sim.9120 · Cited by 26
“For h 0T , we assume a constant hazard over ( 0 , C ) and let h 0T ∼ Log-N ( h 0T , v 2 h ) , since previous studies indicate that it is reasonable to assume a constant hazard during the follow-up period.”
BackgroundJonasch, E. W., Atkins, M. B., Chowdhury, S., & Mainwaring, P. N. (2022) · Cancers · doi:10.3390/cancers14030644 · Cited by 25
“In terms of tolerability of the currently approved CPI/anti-angiogenic combinations, hypertension, fatigue, and diarrhoea were among the most common any grade adverse events (AEs) reported in the phase III trials of avelumab plus axitinib, and pembrolizumab plus axitinib; incidences were generally similar to those in…”
BackgroundMethodResultInfluentialSelf-citationLan, C., Lu, H., Zhou, L., Liao, K., Liu, J., Xie, Z., Liang, H., Zou, G., Yang, T., Xu, Q., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12547 · Cited by 29
“Numerous clinical trials have demonstrated the enhanced efficacy of combining anti-angiogenic treatments with immunotherapy across multiple cancer types, including non-small cell lung cancer (NSCLC) [15], hepatocellular carcinoma [16], and renal cell carcinoma [17].”
BackgroundGrünwald, V., McKay, R. R., Büchler, T., Eto, M., Park, S. H., Takagi, T., Zanetta, S., Keizman, D., Suárez, C., Négrier, S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35288 · Cited by 22
“16 These results emphasize the benefit of immunotherapy-based combination treatments versus sunitinib in particular prognostic groups.”
Self-citationGoebell, P. J., Ivanyi, P., Bedke, J., Bergmann, L., Berthold, D., Boegemann, M., Busch, J. F., Doehn, C., Krege, S., Retz, M. M., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0403 · Cited by 23
Self-citationMassaad, E., Saylor, P. J., Hadzipasic, M., Kiapour, A., Oh, K. S., Schwab, J. H., Schoenfeld, A. J., Shankar, G. M., & Shin, J. H. (2021) · Journal of Neurosurgery Spine · doi:10.3171/2020.12.spine201896 · Cited by 25
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview
Bergmann, L., Weber, S., Hartmann, A., & Ahrens, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1959319 · Cited by 24
“Other IO combinations, such as axitinib/pembrolizumab, axitinib/avelumab, or atezolizumab/bevacizumab, demonstrated relevant superiority in terms of ORR, PFS, and OS compared to sunitinib [9,99,100].”
Tang, B., Mo, J., Yan, X., Duan, R., Chi, Z., Cui, C., Si, L., Kong, Y., Mao, L., Li, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.018 · Cited by 22
Yang, Y., Psutka, S. P., Parikh, A. B., Li, M., Collier, K. A., Miah, A., Mori-Vogt, S., Hinkley, M., Tykodi, S. S., Hall, E. T., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4679 · Cited by 22
Kato, S., Li, B., Adashek, J. J., Cha, S. W., Bianchi-Frias, D., Qian, D., Kim, L., so, T. W., Mitchell, M., Kamei, N., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2052410 · Cited by 24
Kiss, I., Kühn, M., Hrušák, K., & Büchler, T. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100474 · Cited by 24
“100474.(14-74) The cancer types were breast cancer (n 1⁄4 3), colorectal cancer (n 1⁄4 1), gastroesophageal cancer (n 1⁄4 4), hepatocellular cancer (n 1⁄4 1), head and neck carcinoma”
BackgroundKim, T. J., Lee, Y. H., & Koo, K. C. (2022) · Korean journal of urology · doi:10.4111/icu.20220103 · Cited by 22
“While cytokinebased therapy utilizing interferon and interleukin (IL)-2 and targeted molecular therapies that involve tyrosine kinase inhibitors (TKIs), vascular endothelial growth factor (VEGF), and mammalian target of rapamycin inhibitors have shown potential in the metastatic disease setting, tumor resistance of th…”
BackgroundInfluentialJaved, S., Soukhtehzari, S., Fernandes, N., & Williams, K. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-20854-9 · Cited by 22
Jahangir, M., Yazdani, O., Kahrizi, M. S., Soltanzadeh, S., Javididashtbayaz, H., Mivefroshan, A., Ilkhani, S., & Esbati, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02816-3 · Cited by 23
Nakayama, I., & Takahari, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093226 · Cited by 24
First-line ICIs in renal cell carcinoma
Fiorentino, V., Tralongo, P., Larocca, L. M., Pizzimenti, C., Martini, M., & Pierconti, F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2225386 · Cited by 23
“In the phase 3 KEYNOTE−426 trial, 861 patients with metastatic ccRCC were randomly assigned to receive either pembrolizumab and axitinib or sunitinib as their first line of treatment.(33,42) In terms of both PFS and OS, this combination has been demonstrated to be effective throughout a follow-up period of at least 30…”
MethodTargeting HIF-2 Alpha in Renal Cell Carcinoma
Ahmed, R., & Ornstein, M. C. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01106-y · Cited by 22
Krawczyk, K., Śladowska, K., Holko, P., & Kawalec, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1223929 · Cited by 23
“In four trials [CheckMate 9ER (Motzer et al., 2022a; Choueiri et al., 2021; NCT03141177, 1411), KEYNOTE-426 (Rini et al., 2019; Powles et al. 2020; NCT02853331, 2853), CLEAR (Motzer et al., 2021; NCT02811861, 2811) and JAVELIN Renal 101 (Rini et al., 2022; Motzer et al., 2019; NCT02684006, 2684)], TKIs were used in co…”
InfluentialSurvivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review
Güven, D. C., Thong, M. S. Y., & Arndt, V. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01507-w · Cited by 25
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.